How many units of sermorelin per day is normal dosing

Last updated 2026-07-24

How many units of sermorelin should you inject per day?

There's no fixed number of "units" that applies to everyone, because a unit on an insulin syringe is a volume marker, not a fixed dose of drug. It only means something once you know how much sermorelin is dissolved in that vial. Most adult sermorelin protocols aim for 200 to 300 micrograms (mcg) per dose, given once daily by subcutaneous injection, usually at night. That's the dose range referenced in older clinical reviews of sermorelin's use in adult growth hormone insufficiency ^[1]. The "units" figure you actually draw up depends entirely on how concentrated your specific vial is after reconstitution. Here's the practical translation. If a vial is mixed to 1 mg/mL (a common compounding concentration), a 200 mcg dose is 0.2 mL, which is 20 units on a standard U-100 insulin syringe (where 100 units = 1 mL). A 300 mcg dose on that same vial is 30 units. If the vial is mixed more concentrated, say 2 mg/mL, the same 200 mcg dose is only 10 units. This is why your prescriber or pharmacy gives you a specific instruction sheet for your vial rather than a generic "units per day" number that would apply to anyone. The short, honest answer: expect somewhere around 20 to 30 units on a typical reconstitution for a 200-300 mcg dose, but treat that as a starting reference point, not a prescription. Confirm the actual number against your vial's label and your provider's written instructions every time.

Why does sermorelin dosing use mcg, mg, and units all at once?

Three different units show up because three different steps of dosing use different scales. The drug itself is measured in micrograms or milligrams (mass). The syringe measures volume, using units calibrated for insulin (100 units per mL on a standard U-100 syringe). Concentration (mg per mL) is the bridge between the two. Sermorelin ships as a lyophilized (freeze-dried) powder in a vial, typically containing a few milligrams of peptide. A pharmacy or clinic reconstitutes it with bacteriostatic water to a specific final volume, and that reconstitution ratio decides how many mcg live in each unit you draw up. A 5 mg vial mixed with 2 mL of water gives 2.5 mg/mL. Mixed with 5 mL of water, it gives 1 mg/mL. Same vial, same total drug, completely different unit-to-dose math. This is exactly why asking "how many units per day" without naming your concentration doesn't have a single right answer. It's also why dosing errors happen when people switch vial sources or reconstitution volumes without recalculating. If you change pharmacies or your vial's mixing instructions change, redo the math (or ask your provider to redo it for you) before your next injection.

What is a typical sermorelin dose for adults, in mcg?

Clinical literature on sermorelin in adult growth hormone insufficiency describes doses generally in the 200 to 300 mcg per day range, given as a single nightly subcutaneous injection ^[1]. That timing isn't arbitrary. Growth hormone release is naturally pulsatile and highest during early sleep, so sermorelin (which works by stimulating the pituitary to release the patient's own growth hormone, rather than replacing it directly) is dosed to align with that natural nighttime pulse. Pediatric use, the original and best-studied indication, followed weight-based dosing protocols established during sermorelin's development and FDA review under the brand name Geref ^[2]. Adult off-label use for growth hormone insufficiency generally does not scale by body weight in the same way; it tends to use a flat starting dose, adjusted based on response and, where monitored, IGF-1 lab values. One small study of growth hormone secretagogue treatment in hypogonadal men found the therapy raised serum IGF-1 levels during treatment ^[3], which is the expected pharmacological signal that the pituitary is responding. That's a marker of mechanism, not a proxy for any specific outcome like fat loss or strength; the study measured IGF-1, and that's what should be cited from it.

How do you convert mcg to units on an insulin syringe?

The formula is simple once you know your vial's concentration: units needed = (desired dose in mcg / concentration in mcg per mL) x 100. Walk through an example. Say your vial is reconstituted to 2 mg/mL, which is 2,000 mcg/mL. Your target dose is 250 mcg. Divide 250 by 2,000, giving 0.125 mL. Multiply by 100 (units per mL) and you get 12.5 units. Here's a reference table for common reconstitution setups, assuming a 5 mg vial:

Does sermorelin dose depend on body weight, age, or sex?

In pediatric use, yes, weight-based dosing was part of the original studied protocol for children with growth hormone deficiency ^[2]. In adult use, dosing is typically flatter and adjusted by response rather than strict weight-based formulas, though individual prescribers vary in their approach. Age matters less for dose size and more for candidacy and monitoring intensity. Adult-onset growth hormone insufficiency is a defined clinical entity, generally diagnosed through hormone stimulation testing, not a self-diagnosed condition based on fatigue or slow recovery from workouts. A clinician who orders labs (IGF-1, and sometimes a GH stimulation test) before prescribing is doing it the right way. Sex-based dosing differences aren't well established in the sermorelin literature specifically. Related work on growth hormone secretagogues in hypogonadal men focused on male patients and IGF-1 response ^[3], so it doesn't tell you much about dosing in women. Anyone considering this therapy should expect an individualized starting dose followed by adjustment, not a one-size number pulled from a forum post.

What happens if you take too much or too little sermorelin?

Too little and you likely just don't get a meaningful pituitary response, meaning the therapy doesn't do much of anything measurable. Too much doesn't turn sermorelin into a stronger drug the way overdosing on some medications intensifies effect; growth hormone-releasing hormone analogs work through receptor-mediated pituitary stimulation, and that system has natural feedback limits. That said, more isn't better and isn't free. Injection site reactions, headache, flushing, and mild nausea are the more commonly reported issues with GHRH analogs and secretagogues in general. Long-term, high-dose growth hormone exposure (this applies more directly to HGH itself, and to chronic misuse patterns, rather than typical sermorelin dosing) has been linked in case reports to problems like bone and soft tissue changes; one recent case report described cervical osteophyte-related swallowing difficulty in a long-term growth hormone user ^[4], which is a useful reminder that growth-axis therapies aren't inert just because they're "natural" secretagogues rather than synthetic hormone. If you miss a dose, the standard advice for once-daily GHRH therapy is to skip it and resume the next scheduled dose rather than doubling up, though you should follow your specific prescriber's instructions rather than general guidance, since protocols vary. For a fuller look at what side effects show up over months of use, see sermorelin long-term side effects.

How does sermorelin dosing compare to HGH dosing?

This is really the central question underneath "how many units per day," because a lot of people asking about sermorelin units are actually trying to compare it to HGH (somatropin) units, and the two aren't interchangeable in dose or in mechanism. HGH is the hormone itself, injected directly, typically dosed in IU (international units) per day, commonly in a range like 1 to 6 IU daily for approved adult indications, with exact dosing set by an endocrinologist based on diagnosis, weight, and labs. Sermorelin is not growth hormone. It's a growth hormone-releasing hormone analog, meaning it signals the pituitary to make and release the body's own GH, and it only works if the pituitary is still capable of responding ^[1]. That mechanism difference matters for dosing philosophy. HGH dosing is about titrating a direct hormone replacement. Sermorelin dosing is about stimulating an endogenous pulse, which is inherently a gentler, more self-limited process because the pituitary retains some of its own regulatory feedback. That's also sermorelin's real weakness as a comparison: it's a milder intervention. Where HGH bypasses the pituitary entirely, sermorelin depends on having a pituitary that still works well, and in patients with primary pituitary failure or older age-related decline, sermorelin's effect ceiling is lower. Reviews describe it as a more physiologic approach to raising GH and IGF-1 ^{[1] [3]}, not as an equivalent-strength substitute for HGH itself. On a here's-what-I'd-actually-consider basis: sermorelin makes sense as a lower-intensity, prescriber-monitored option for adults with confirmed insufficiency who want to work with the body's own regulatory system. It is not a shortcut to HGH-level effects at a lower unit count, and anyone marketing it that way is overselling the pharmacology. For a broader look at how the two are used, see sermorelin and sermorelin peptide before and after.

Is sermorelin FDA-approved, and does that affect dosing guidance?

Sermorelin was FDA-approved and marketed in the United States under the brand name Geref. It's important to be precise here: Geref was discontinued by its manufacturer for business reasons, not withdrawn by FDA for a safety problem. You can check current approval status yourself in Drugs@FDA ^[5], the agency's official database of approved drug products. Because the branded product is discontinued, sermorelin used today is almost entirely compounded, meaning it's prepared by a licensed compounding pharmacy under a prescription rather than dispensed as an FDA-approved packaged product with an FDA-approved label and dosing insert. That has a direct effect on the "units per day" question: without a manufacturer's package insert, dosing depends on the compounding pharmacy's specific concentration and your prescriber's protocol, not on a single FDA-set number. Compounded sermorelin is regulated differently than approved drugs. Under section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a) ^[6], licensed pharmacies can compound drugs from bulk substances for individual patients with a valid prescription. FDA maintains lists of bulk drug substances that can and cannot be used this way under 21 CFR 216.23 and 216.24 ^{[7] [8]}, and separately publishes bulk substances nominated for 503A compounding ^[9]. This regulatory path is real and legal, but it also means product quality and exact concentration can vary more between pharmacies than it would for an FDA-approved, mass-manufactured drug. That's a real practical reason to source through a provider-reviewed pathway rather than an unregulated online seller; see best place to buy sermorelin and sermorelin reviews for more on vetting sources.

Can you combine sermorelin with other peptides, and does that change the dose?

Sermorelin is sometimes combined with GHRP-class secretagogues or with other GHRH analogs like tesamorelin in off-label protocols, on the theory that stimulating the pituitary through more than one receptor pathway produces a stronger GH pulse than either agent alone. This is a real practice in some clinics, but it is not the same thing as a validated combination therapy with an established, tested combined dose. A 2026 review of therapeutic peptides in orthopaedic and musculoskeletal contexts surveys applications and challenges facing peptide therapeutics broadly, including translational hurdles that apply to combination use ^[10]. Separately, a 2026 review in Sports Medicine specifically examined the safety and efficacy evidence for approved and unapproved peptide therapies used for musculoskeletal injury and athletic performance, highlighting how uneven the evidence base is across different peptides used in this space ^[11]. If you're considering stacking, the dose of each individual peptide typically does not simply add together in a predictable way, and a prescriber managing the combination should be setting doses based on monitoring, not a fixed ratio pulled from an online protocol. For a dedicated look at this exact question, see can stack tesamorelin and sermorelin.

How is sermorelin dose adjusted over time?

Sermorelin dosing typically starts conservative and is adjusted based on clinical response and, where used, lab monitoring of IGF-1. Because sermorelin's mechanism depends on a functioning pituitary responding to a releasing hormone signal, dose adjustments are about finding the level that produces an adequate pulse, not about pushing toward a maximum tolerated dose the way some drug titrations work. A study of growth hormone secretagogue treatment in hypogonadal men reported that treatment raised serum IGF-1 levels ^[3], and IGF-1 monitoring is the practical tool prescribers lean on to judge whether a dose is doing anything measurable. If IGF-1 doesn't move meaningfully after a reasonable trial period, the dose may be increased within the studied range, or the therapy may be reconsidered altogether, since pushing a non-responsive pituitary harder with more mcg isn't a guaranteed fix. There isn't strong published guidance on precise titration schedules (how many weeks between adjustments, exact mcg increments) specific to adult off-label sermorelin use, and that's a real gap in the evidence, not something to paper over. Anyone on this therapy should expect periodic follow-up, not a "set it and forget it" nightly injection for years without reassessment.

What research gaps exist around sermorelin dosing?

The honest picture is that sermorelin's best-established dosing evidence comes from two eras: its original pediatric development for idiopathic growth hormone deficiency in the 1990s ^[2], and a smaller body of adult growth hormone insufficiency literature from the mid-2000s ^[1]. Both predate the current wave of interest in peptide therapies for general wellness, body composition, and performance, and neither was designed to answer today's most common reader question, which is really "what's the right dose for a healthy adult without diagnosed deficiency." Much of the more recent literature on GHRH analogs actually comes from an unexpected direction: anti-doping science. Multiple 2020s papers describe increasingly sensitive mass spectrometry methods for detecting GHRH analogs in urine, plasma, and blood at picogram levels ^{[12] [13] [14] [15]}, and a 2021 review specifically covers advances in detecting synthetic GHRH analogs ^[16]. This tells you two things. First, GHRH analogs including sermorelin are on doping-control radar, which is a real regulatory fact worth knowing if you're a tested athlete. Second, a meaningful share of research funding in this space is going toward detection rather than toward clinical dosing optimization for general adult use, which is exactly the kind of evidence gap a careful reader should recognize rather than have papered over with confident-sounding numbers. A separate, more speculative line of research looked at sermorelin in recurrent glioma, an oncology context completely unrelated to routine adult dosing ^[17], which shows that sermorelin research spans some very different applications, and readers should be careful not to conflate findings from one context with another.

Frequently asked questions

How many mcg of sermorelin should I take per day?

Most adult protocols target 200 to 300 mcg per day, given as one subcutaneous injection at night, a range referenced in clinical literature on sermorelin for adult growth hormone insufficiency. Your actual dose depends on your prescriber's assessment, your labs, and how you respond, so treat this as a general reference range rather than a personal prescription.

How many units is 200 mcg of sermorelin?

It depends entirely on your vial's concentration. On a vial mixed to 1 mg/mL, 200 mcg is 20 units on a standard U-100 insulin syringe. On a vial mixed to 2.5 mg/mL, the same 200 mcg dose is only 8 units. Always check your specific vial's concentration before drawing up a dose.

Is sermorelin dosed differently than HGH?

Yes. HGH is dosed in IU as a direct hormone replacement, commonly in the range of 1 to 6 IU daily for approved adult uses. Sermorelin is a growth hormone-releasing hormone analog dosed in mcg, typically 200 to 300 mcg nightly, and it works by stimulating the pituitary rather than replacing the hormone outright.

Why do sermorelin vials list different concentrations?

Because compounding pharmacies reconstitute the same milligram amount of freeze-dried sermorelin with different volumes of bacteriostatic water, producing different mg/mL concentrations. A 5 mg vial mixed with 1 mL is far more concentrated than the same vial mixed with 5 mL, which changes how many units correspond to the same mcg dose.

Was sermorelin ever FDA-approved?

Yes, sermorelin was FDA-approved and sold under the brand name Geref. The manufacturer discontinued the branded product for business reasons; it was not withdrawn by FDA over a safety finding. Today's sermorelin is compounded by licensed pharmacies rather than sold as an approved packaged drug, which you can verify in FDA's Drugs@FDA database.

What happens if I inject too many units of sermorelin?

Sermorelin's pituitary-stimulation mechanism has natural feedback limits, so an excess dose doesn't scale effect the way overdosing on some drugs does. But higher doses can still increase side effects like injection site reactions, flushing, or headache. If you think you've significantly overdosed, contact your prescriber rather than guessing at a correction.

Can sermorelin dosing be based on body weight?

In pediatric growth hormone deficiency treatment, weight-based dosing was part of the original studied protocol. In adult use, dosing tends to be a flat starting dose adjusted by clinical response and IGF-1 monitoring rather than a strict weight-based formula, though practices vary by prescriber.

How do I convert my sermorelin dose from mcg to insulin syringe units?

Divide your target dose in mcg by your vial's concentration in mcg/mL, then multiply by 100. For example, a 250 mcg dose from a 2,000 mcg/mL (2 mg/mL) vial works out to 12.5 units. Always confirm this math against your specific vial's label.

Does sermorelin dosing change if I combine it with other peptides?

It can, but there's no standardized combined-dose formula. Sermorelin is sometimes paired with GHRP-class secretagogues or other GHRH analogs like tesamorelin in off-label protocols, and a prescriber managing that combination should set each dose individually based on monitoring rather than a fixed online ratio.

How is a sermorelin dose adjusted over time?

Prescribers generally start conservative and adjust based on clinical response and IGF-1 lab monitoring, since sermorelin's effect depends on a functioning pituitary responding to the signal. There isn't strong published guidance on a precise titration schedule for adult off-label use, so expect periodic reassessment rather than a fixed escalation plan.

Is sermorelin tested for in anti-doping screening?

Yes. Multiple recent studies describe sensitive mass spectrometry methods developed specifically to detect GHRH analogs, including sermorelin, in urine, plasma, and blood, some down to picogram-per-milliliter levels. This is an active area of anti-doping science, which matters for any tested athlete considering this therapy.

Why don't sermorelin sellers just tell me a units-per-day number?

Because units depend on your vial's specific concentration after reconstitution, which varies by pharmacy and mixing instructions. A responsible seller or prescriber gives you mcg targets and calculates your specific unit dose for your vial, rather than quoting a generic units number that could be wrong for a different concentration.

Sources

1. Clinical Interventions in Aging, 2006 (PMID 18046908): Sermorelin for adult-onset growth hormone insufficiency is generally dosed around 200-300 mcg per day via subcutaneous injection, working through pituitary stimulation rather than direct hormone replacement.
2. BioDrugs, 1999 (PMID 18031173): Sermorelin's original studied use was in diagnosis and treatment of children with idiopathic growth hormone deficiency, using weight-based dosing protocols.
3. American Journal of Men's Health, 2017 (PMID 28830317): Growth hormone secretagogue treatment in hypogonadal men raised serum IGF-1 levels during treatment.
4. Frontiers in Surgery, 2026 (PMID 42465868): A case report describes anterior cervical osteophyte-related dysphagia in a long-term growth hormone user, illustrating a real risk of chronic growth-axis stimulation.
5. FDA, Drugs@FDA database: Drugs@FDA is the FDA's official database for checking current approval status of drug products, relevant to confirming Geref's history and discontinuation.
6. Cornell Law School Legal Information Institute, 21 U.S.C. 353a: Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacies to compound drugs from bulk substances for individual patients under a valid prescription.
7. eCFR, 21 CFR 216.23 (503A Bulks List): FDA maintains a regulatory list of bulk drug substances that can be used in compounding under section 503A.
8. eCFR, 21 CFR 216.24 (503B Bulks List): FDA maintains a separate bulks list governing substances usable in 503B outsourcing facility compounding.
9. FDA, bulk drug substances nominated for use in compounding: FDA publishes and updates a list of bulk drug substances nominated for use in compounding under section 503A.
10. Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, 2026 (PMID 41490200): A 2026 review surveys therapeutic peptide applications, translational challenges, and future directions in orthopaedics.
11. Sports Medicine, 2026 (PMID 41966639): A 2026 review examined safety and efficacy evidence for approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance.
12. Analytical and Bioanalytical Chemistry, 2016 (PMID 26879649): Researchers developed immunoaffinity purification and LC-HRMS/MS methods to qualitatively identify growth hormone-releasing hormones in human plasma.
13. Journal of Pharmaceutical and Biomedical Analysis, 2022 (PMID 35298973): An antibody-free, ultrafiltration-based nanoLC-HRMS/MS assay was developed to detect growth hormone-releasing hormones in urine at low picogram-per-milliliter concentrations.
14. Analytical Biochemistry, 2023 (PMID 37806509): A cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS method was developed for detecting GHRHs in urine samples.
15. Journal of Mass Spectrometry, 2024 (PMID 38197510): Chromatographic-mass spectrometric methods have been developed to analyze peptidic analytes between 2-10 kDa, including GHRH-class peptides, in doping control urine samples.
16. Drug Testing and Analysis, 2021 (PMID 34665524): A 2021 review covers advances in the detection of synthetic growth hormone-releasing hormone analogs.
17. Annals of Translational Medicine, 2021 (PMID 33842627): Sermorelin has been studied as a potentially effective drug in patients with recurrent glioma, an oncology context distinct from routine adult dosing.